Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy
Open Access
- 11 March 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (6) , 723-731
Abstract
Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE. A retrospective evaluation of consecutive adult patients with medically refractory HE referred for PSS embolization at a tertiary center was performed (2003‐2015). Patient data collected included the type of HE, medications, Model for End‐Stage Liver Disease (MELD) score, shunt type, embolization approach, and materials used. Outcomes of interest were immediate (7 days), intermediate (1‐4 months), and longer‐term (6‐12 months) effectiveness and periprocedural safety. Effectiveness was determined based on changes in hospitalization frequency, HE medications, and symptoms. Twenty‐five patients with large PSS were evaluated for shunt embolization. Five were excluded due to high MELD scores (n = 1), comorbid conditions (n = 1), or technical considerations (n = 3). Of 20 patients who underwent embolization, 13 had persistent and 7 had recurrent HE; 100% (20/20) achieved immediate improvement. Durable benefit was achieved in 100% (18/18) and 92% (11/12) at 1‐4 and 6‐12 months, respectively. The majority (67%; 8/12) were free from HE‐related hospitalizations over 1 year; 10% developed procedural complications, and all resolved. Six developed new or worsening ascites. In conclusion, PSS embolization is a safe and effective treatment strategy that should be considered for select patients with medically refractory HE. Liver Transplantation 22 723–731 2016 AASLD.Keywords
This publication has 9 references indexed in Scilit:
- Definition and Nomenclature of Hepatic EncephalopathyJournal of Clinical and Experimental Hepatology, 2015
- Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long‐term outcomes in 14 patientsHepatology Research, 2013
- Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacyHepatology, 2013
- Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statementAlimentary Pharmacology & Therapeutics, 2011
- Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shuntsLiver International, 2007
- High Prevalence of Spontaneous Portal-Systemic Shunts in Persistent Hepatic Encephalopathy: A Case-Control Study *Hepatology, 2005
- Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathyCardioVascular and Interventional Radiology, 1997
- CLINICAL AND PORTAL HEMODYNAMIC FEATURES IN CIRRHOTIC-PATIENTS HAVING A LARGE SPONTANEOUS SPLENORENAL AND OR GASTRORENAL SHUNT1986
- Spontaneous portosystemic shuntDigestive Diseases and Sciences, 1981